847027-69-4

Upstream product

• 24461-61-8 phenylglycine methyl ester 
• 144073-04-1 (RS)-2-amino-2-phenyl-4-penten-1-ol 
• 193421-73-7 α-allylphenylglycine ethyl ester 
• 686320-24-1 C₁₂H₁₃NO₄ 
• 686320-25-2 C₁₈H₂₃NO₆ 
• 686320-28-5 4-(2,5-difluorophenyl)-2-phenyl-2-[(1,1,2,2-tetramethylpropoxy)methyl]-2,5-dihydro-1H-pyrrole 
• 845256-74-8 tert-Butyl [2-(hydroxymethyl)-1-methylpiperidin-4-yl]methylcarbamate 
• 686320-23-0 4-Allyl-4-phenyl-1,3-oxazolidin-2-one 
• 686320-26-3 7a-phenyldihydro-1H-pyrrolo[1,2-c][1,3]oxazole-3,6(5H)-dione 
• 845256-51-1 6-methylene-7a-phenyltetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one 
• 845256-50-0 methyl 4-methylene-2-phenylpyrrolidine-2-carboxylate 
• 845256-48-6 (2S)-4-(2,5-difluorophenyl)-2-phenyl-2-[(1,1,2,2-tetramethylpropoxy)methyl]-2,5-dihydro-1H-pyrrole 
• 686320-27-4 6-(2,5-difluorophenyl)-7a-phenyl-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazole-3-one 
• 845256-49-7 (2S)-2-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-(2,5-difluorophenyl)-2-phenyl-2,5-dihydro-1H-pyrrole-1-carbonyl chloride 

Relevant academic research and scientific papers

MITOTIC KINESIN INHIBITORS

The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositi